Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides

Khyati Kapoora, Janet S. Finer-Moores, Bjorn P. Pedersenb,1, Laura Caboni, Andrew Wight2, Roman C. Hilligd, Peter Bringmandd, Iring Heisler, Thomas Müllera, Holger Siebeneichera, and Robert M. Strouda

aDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; bDepartment of Molecular Biology and Genetics, Aarhus University, Aarhus DK-8000, Denmark; cBayer Pharma AG, Drug Discovery, 13353 Berlin, Germany; dBayer Pharmaceuticals, Biologics Research, San Francisco, CA 94158; and eBayer Pharma AG, Drug Discovery, 42096 Wuppertal, Germany

Contributed by Robert M. Stroud, March 8, 2016 (sent for review February 4, 2016; reviewed by Susan K. Buchanan and Lan Guan)

Cancerous cells have an acutely increased demand for energy, leading to increased levels of human glucose transporter 1 (hGLUT1). This up-regulation suggests hGLUT1 as a target for therapeutic inhibitors addressing a multitude of cancer types. Here, we present three inhibitor-bound, inward-open structures of WT-hGLUT1 crystallized with three different inhibitors: cytochalasin B, a nine-membered bicyclic ring fused to a 14-membered macrocycle, which has been described extensively in the literature of hGLUTs, and two previously undescribed Phe amide-derived inhibitors. Despite very different chemical backbones, all three compounds bind in the central cavity of the inward-open state of hGLUT1, and all binding sites overlap the glucose-binding site. The inhibitory action of the compounds was determined for hGLUT family members, hGLUT1-4, using cell-based assays, and compared with homology models for these hGLUT members. This comparison uncovered a probable basis for the observed differences in inhibition between family members. We pinpoint regions of the hGLUT proteins that can be targeted to achieve isoform selectivity, and show that these same regions are used for inhibitors with very distinct structural backbones. The inhibitor cocomplex structures of hGLUT1 provide an important structural insight for the design of more selective inhibitors for hGLUTs and hGLUT1 in particular.

X-ray structure | glucose facilitator | human MFS transporter | cytochalasin B | GLUT inhibitor

Human glucose transporter 1 (hGLUT1) belongs to a family of homologous sugar transporters or cotransporters found in both prokaryotes and eukaryotes (1). It is a uniporter that transports glucose from the ECM into cells (2, 3), hGLUT1 is the ubiquitous glucose transporter in the human body and is absolutely essential for cell viability (4). The increased demand for glucose in cancer cell lines, as well as in benign and malignant tumor cells, results in up-regulation of glucose transporter expression, especially for hGLUT1 (5). Cancerous cells grow and multiply faster than normal cells, resulting in an acutely increased demand for energy (6). The up-regulation of hGLUT1 upon increased demand for glucose highlights it as an important prognostic indicator in several cancer types (7–10), as well as a potential new target for therapeutic inhibitors.

Previous biochemical studies have shown that cytochalasin B and forskolin inhibit hGLUT1-mediated sugar transport in RBCs by binding at or close to the hGLUT1 sugar export site (11, 12). Recent structural studies on hGLUT1 have been focused toward elucidating the glucose-binding site. The apo structure of hGLUT1 was recently reported at 3.2 Å (13). It features an inward-open conformation that shows the standard canonical fold of a major facilitator superfamily transporter. It was designed with two point mutations, N45T and E329Q, to facilitate crystallization. This structure was a milestone in the field, and it serves as a blueprint for development of therapeutic agents because it marks the putative binding site for the glucose moiety.

The structure of another glucose transporter, hGLUT3, bound to the α- and β-anomers of glucose was very recently reported in an outward-occluded state (14). The glucose-binding site was predicted to be similar to the site proposed for hGLUT1, and many of the residues lining the central cavity were conserved.

Here, we report the structure determination of WT-hGLUT1 co-crystallized with three inhibitors, including cytochalasin B. Cytochalasin B is a cell-permeable mycotoxin and features a macrocyclic ring structure (15) (Fig. 1A). It has been used extensively in the literature of hGLUTs, and hGLUT1 in particular, and this work presents, for the first time to our knowledge, the binding mode of this essential tool in the field. Two inhibitors never described before in the literature, glucose transporter-inhibitor 1 (GLUT-i1) and glucose transporter-inhibitor 2 (GLUT-i2), are based on a Phe-amide core scaffold and were identified in a high-throughput screening campaign for hGLUT1 inhibitors described here (Fig. 1A–C). The structures are all in an “inward-facing” conformation at a resolution of 2.9-3.0 Å and provide a clear model for interactions with residues that mainly belong to the glucose substrate-binding site (Fig. 1D).

The crystal structures define the inhibitor-binding modes in the presence of glucose, such that mainly belong to the glucose substrate-binding site (Fig. 1D).

Significance

This paper reports the first structure of WT-human glucose transporter 1 (hGLUT1), to our knowledge, co-crystallized with inhibitors. The structures provide a template to develop therapeutic inhibitors applicable to cancers, because cancer cells become dependent on greatly increased glucose consumption. This dependence results in up-regulation of glucose transporter expression, especially hGLUT1. The bound inhibitors include the natural compound cytochalasin B and two of a series of previously undescribed organic compounds that bind in the submicromolar range. Our results emphasize that modulation of glucose import by hGLUTs should focus on making good interaction points for compounds and that the actual chemical backbone of the inhibitor is of less importance.


Reviewers: S.K.B., National Institutes of Health; and L.G., Texas Tech University Health Sciences Center. Conflict of interest statement: R.C.H, P.B., I.H., T.M., and H.S. are or have been employees and stockholders of Bayer AG.

Data deposition: The atomic coordinates and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes SEQI (hGLUT1) with inhibitor cytochalasin B, SEQG (hGLUT1) with inhibitor GLUT-i1), and SEQH (hGLUT1 with inhibitor GLUT-i2).

1Present address: Aarhus Institute of Advanced Studies, Aarhus University, Aarhus DK-8000, Denmark.
2Present address: Seattle Genetics, Bothell, WA 98021.
3To whom correspondence should be addressed. Email: stroud@msg.ucsf.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1603735113/-/DCSupplemental.
inhibitors of hGLUT1 by indirect measurement of hGLUT1 inhibition (SI Materials and Methods). Crystallization screens were attempted for WT-hGLUT1 with various representatives of this HTS hit cluster and with several well-known compounds that were shown to be inhibitors of glucose uptake. The IC\textsubscript{50} values of cytochalasin B (Fig. 1A), as well as the GLUT-i1/i2 (Fig. 1B and C), on HEK 293 cells were determined against hGLUT1-4 using an indirect cell-based assay in which ATP levels were measured using luminescence of luciferin. All compounds were shown to be very effective inhibitors of hGLUT1, with IC\textsubscript{50} values in the nanomolar range (Table 1). All three compounds had submicromolar IC\textsubscript{50} against hGLUT1 and hGLUT4, but 10- to 100-fold higher IC\textsubscript{50} for hGLUT2 and intermediate IC\textsubscript{50} against hGLUT3 (Table 1). We observed that cytochalasin B and GLUT-i1 both competed for the same binding pocket of hGLUT1 when tested against increasing concentrations of glucose (Table 2 and SI Materials and Methods).

Crystal Structure of hGLUT1 with Cytochalasin B. The crystal structure of hGLUT1 bound to cytochalasin was determined by molecular replacement using the published structure of apo-hGLUT1 as a search model. hGLUT1 lies in the same inward-open conformation as the previously reported apo-hGLUT1 double mutant (13) (rmsd = 0.6 Å for 447 aligned Cαs). Thus, in our hands, the mutations were not necessary to obtain well-differacting crystals that capture the inward-facing conformation.

Cytochalasin B is a macroclide ring fused to a nine-membered bicyclic ring, and density for the bicyclic ring system and the macrolide ring was clear in the Fo-Fc map calculated after refinement of the protein (Fig. S2A). Our fit of cytochalasin B to density (Fig. 2A) was supported by the fact that Trp388 and Trp412 in transmembrane (TM) 10 and TM11, respectively, surround the binding site and contribute to hydrophobic interactions with the ligand (Fig. 3A). These residues have been shown to be labeled upon exposure to photolabile, radioactively labeled cytochalasin B in several biochemical studies (17, 18).

Crystal Structure of hGLUT1 with GLUT-i1. Similar to the cytochalasin B complex structure, hGLUT1 lies in an inward-open conformation, with an rmsd of 0.6 Å for 447 Cαs aligned to the apo form (13). With GLUT-i1, unbiased difference electron density (phased on the protein alone) revealed a trilobed density in the central cavity (Fig. S2B). The strong ligand density from the Phe amide looked quite distinct in shape from cytochalasin B. GLUT-i1, being a nearly threefold symmetrical molecule, can be fitted with various permutations of its three rings into this density, but with one best orientation, which refined to a free R-factor of 29.5% (Fig. 2B). In the published apo-hGLUT1 structure, a detergent molecule that included a ß-NG occupied the density for ß-NG, occupied the binding site (13). Because we also used ß-NG to produce crystals, our refinement included an assessment

Table 1. IC\textsubscript{50} values of inhibition of glucose transport in the presence of cytochalasin B, GLUT-i1, and GLUT-i2 for hGLUT family members hGLUT1-4 (n = 3)
Table 2.  IC₅₀ values (µM) of inhibition of glucose transport in the presence of increasing concentrations of glucose

<table>
<thead>
<tr>
<th>hGLUT1 inhibitor</th>
<th>Glucose, 0.02 mM Glucose, 0.1 mM Glucose, 1 mM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytochalasin B</td>
<td>0.11  0.5  2.2</td>
</tr>
<tr>
<td>GLUT-i1</td>
<td>0.27  1.3  5.1</td>
</tr>
</tbody>
</table>

of the possibility that β-NG occupied the observed density, either partially or completely. There is density at the positions expected for the glucose-ring substituents (Fig. S3A), but placing glucose in the site produced no density for the nonyl chain in the residual Fo-Fc density (Fig. S3B), and joint refinement of partially occupied β-NG and GLUT-i1 yielded an occupancy of 0.8 for GLUT-i1 compared with an occupancy of 0.2 for β-NG, no improvement in the free R-factor, and extra positive difference density in several parts of the inhibitor-binding site. We conclude that β-NG is not bound. Rather, the positive difference density at the flavophenyl ring-binding site may result from unmodeled, partially occupied water molecules.

Crystal Structure of hGLUT1 with GLUT-i2. To confirm the fit of the nearly symmetrical GLUT-i1 to density, we crystallized hGLUT1 in the presence of GLUT-i2, a bromine-containing variant of GLUT-i1. The model was built and refined to 3.0 Å. Due to the additional bromine atom, this compound is less symmetrical and generated strong additional electron density corresponding to the bromine (Fig. S2C). The refined bromine B-factor was high, and we did not observe a peak above noise level for the bromine in an anomalous difference map. When the B-factor of the bromine was set to the B-factor of the ring atom to which it was attached, the bromine occupancy that yielded a clean Fo-Fc map was 0.6. We speculate that the bromine might have partially detached from the inhibitor during data collection due to the high-energy synchrotron X-ray beam. The inhibitor-binding site overlaps the binding site of GLUT-i1. GLUT-i1/2 binding primarily relies on hydrophobic contacts with hGLUT1 (Fig. 3 B and C).

Difference Maps Between Three Structures. To investigate the orientation of these inhibitor compounds in the binding site further, we generated (Fo-Fo)calc difference maps between the three ligand-bound structures, where Fo and Fo are observed amplitudes for two compared structures. All three crystal structures were highly isomorphous; hence, these maps sensitively show the differences at the inhibitor-binding site. Because GLUT-i1 and GLUT-i2 both belong to the same class of compounds and are very similar in structure, the map clearly shows the presence of high integrated electron density for bromine at the standard contour levels of 3σ (Fig. S4A). Cytochalasin B minus GLUT-i1 shows the large negative difference electron density for each of the three phenyl rings and positive density for the cytochalasin B (Fig. S4B). Similar difference densities were found in the map between cytochalasin B and GLUT-i2 (Fig. S4C). The difference maps thus clearly support our placement of inhibitors in the maps.

Homology Modeling of hGLUT2-4. We sought to determine whether the inhibitor–hGLUT1 interactions revealed in the crystal structures accounted for the differences in IC₅₀ of the inhibitors vs. other hGLUT family members. We generated homology models of hGLUT2, hGLUT3, and hGLUT4 in an inward-open conformation based on the crystal structures of ligand-bound hGLUT1. Compounds were docked into the models, and ∆G free energies were calculated using the molecular mechanics generalized Born surface area (MM-GBSA) algorithm for binding to each of the four hGLUTs (Table S1). Docking calculations were able to reproduce the hGLUT1 crystallographic conformation successfully with an rmsd of 0.46 Å for cytochalasin B, 0.28 Å for GLUT-i1, and 0.21 Å for GLUT-i2. This consistency supports the notion that the crystal structure of hGLUT1 can be relevant for the design of better inhibitors of glucose uptake. Other docked conformations of these three compounds were ranked poorly due to the disruption of key contacts, especially with four crucial amino acids in the binding site: Asn411, Thr137, Gln282, and Trp388. The crystallographic conformations are favorable due to hydrogen bonds and the π-π stacking network in the binding site (Figs. 4 and 5 and Fig. S5).

Many of the amino acid side chains and their disposition in the four hGLUTs are conserved. However, hGLUT2 shows more hydrophobic interactions than hGLUT1, hGLUT3, and hGLUT4, signaled by substitution of a His (His311 in hGLUT2) for Gln279 (hGLUT1) in TM7. His311 changes the conformation of Trp388 due to the increased steric hindrance of His. Because the indole of Trp388 forms conserved hydrophobic contacts with all compounds, the observed altered conformation in hGLUT2 may result in generally weaker binding of these compounds to hGLUT2. Thr137 (hGLUT1) is substituted by Ser in hGLUT2 and hGLUT4, and both residues form polar interactions with the OH group of cytochalasin B (Fig. 4).

Calculated predicted binding energies showed a preference of GLUT-i1 and GLUT-i2 for hGLUT1 and hGLUT4, whereas hGLUT2 and hGLUT3 presented similar and lower binding energies (Table S1). The predicted ∆G energy values, although not directly comparable to observed binding energies, indicate that the ranking of these compounds is in line with their experimentally determined IC₅₀s (Table 1). The interactions with cytochalasin B gave calculated energies that reiterate the generally weaker binding of cytochalasin B to hGLUT2. In hGLUT2, the cytochalasin B is positioned closer to Ser169 (TM4) due to Trp388 being pushed toward the inside of the pocket. In this position, the compound loses hydrogen bond contacts between the azole carbonyl and amino acids, Q314 and N320 (Fig. 4).

Discussion

We succeeded in crystallizing full-length WT-hGLUT1 with cytochalasin B, a natural product inhibitor (Fig. 4A). We also crystallized hGLUT1 with GLUT-i1 and GLUT-i2, which belong to the Phe amide class of compounds and inhibit cellular glucose uptake with IC₅₀ values of 0.07 mM and 1.40 nM, respectively (Fig. 4 B and C). Even though GLUT-i1, with a three-ring structure of 420 Da, is much larger than glucose (180 Da), the 5-fluoro-phenyl ring nicely overlaps the glucose-binding site. The glucose site interacts predominantly with the C-terminal domain of hGLUT1. As in other secondary transporters, the binding site of this uniporter is specific for its natural substrates (19). By using intermediate water molecules, glucose achieves selectivity within a much larger binding site than the substrate. The resulting relatively weak binding site [Kᵢ ≈ 35.7 mM (20)] may allow effi- cient glucose transport without blockade.

The phenyl ring of GLUT-i1 binds between helix TM11 in the C-terminal domain and helix TM4 in the N-terminal domain, and 2-hydroxy-phenyl is sandwiched between His160 in TM5 and Trp388 in TM10 (Fig. 3B). Trp388 is a conserved residue in the
hGLUT family located in the mobile C-terminal segment of the discontinuous helix TM10. In the glucose-bound occluded states of hGLUT3 vs. unbound hGLUT3, the counterpart of Trp388 rotates into the channel and forms a hydrogen bond to the glucose substrate (14). GLUT-i1 could therefore block the movement of Trp388, and block rotation of this segment of TM10 into the central cavity.

In our WT structure, these interactions that displace TM10 may have compensated for the changes made by the mutation E325Q that was introduced to fix the conformation of apo-hGLUT1. Binding of the large inhibitor molecule can prop open the central cavity and inhibit the alternate access mechanism, thus inhibiting glucose transport. Trp388 in TM10 is a key binding determinant for all three inhibitors; thus, the inhibitors compete with glucose at the central substrate-binding site. The inhibitors likely cannot make similar hydrophobic or \( \pi - \pi \) interactions with Trp388 when the hGLUT transporters are in outward-open conformations because in the outward-open conformation of the closely related hGLUT3, the face of the Trp388 indole ring is inaccessible (14). It is widely accepted that cytochalasin B binds only to inward-open conformations of hGLUT1 (12).

Despite their different chemical structures, cytochalasin B, GLUT-i1, and GLUT-i2 overlap each other and the proposed glucose substrate site in the central cavity. The published outward-occluded structure of hGLUT3 shows that bound glucose overlaps the cyclohexane ring of cytochalasin B in our model of hGLUT3 based on our structure of cytochalasin B-hGLUT1. The macrolide ring overlaps the linkers between the three rings in GLUT-i1 and GLUT-i2 (Fig. S6). An overlay of all three inhibitors in the binding site shows that there are conserved \( \pi - \pi \) interactions with hGLUT1 (Fig. S6). The main interactions observed with GLUT-i1 are \( \pi - \pi \) stacking interactions of the phenyl and phenol groups with conserved Trp388 and of the fluorophenyl group with Phe379, whereas for cytochalasin B, there are hydrogen bond interactions with Thr137 and Trp388. Hydrophobic interactions with Asn411 and Trp412 are prominent binding determinants for all three inhibitors (Fig. S6). Additionally, there is a \( \pi - \pi \) interaction between GLUT-i1/2 and His160 that is not used in the case of cytochalasin B. Most of these residues are conserved across hGLUT1-4 with few variations, (hGLUT2, hGLUT3, and hGLUT4 display 83%, 93%, and 85% sequence identity, respectively, to hGLUT1); however, the compounds show some selectivity between these proteins, inviting the quest for differences between the hGLUTs that can be exploited for generation of more selective compounds.

Trp388 and Trp412 of hGLUT1 are conserved across several homologous sugar transporters. The corresponding Trps of Escherichia coli GalP, Trp371, and Trp395, contribute to fluorescence quenching upon cytochalasin B binding. Their mutation to Phe results in decreased affinity for cytochalasin B and, in the case of W371F,
decreased affinity of the inward-facing side of GalP for D-gal (21). These results are consistent with our hGLUT1-cytochalasin B structure and suggest similar cytochalasin B-binding modes in GalP and hGLUT1.

E. coli hGLUT1 homologs AraE and GalP are inhibited by cytochalasin B, whereas XylE is not. Highly conserved Asn394 (Asn411 in hGLUT1) was identified as a likely determinant of cytochalasin B binding because it is substituted by Gln in XylE, and mutation of Asn394 to Gln in GalP resulted in a 40- to 50-fold decrease in inhibition by cytochalasin B (22). Asn411 is 3.4 Å from cytochalasin B in our hGLUT1 complex structure. A Gln at this position would impinge on the cytochalasin B-binding site, altering the binding mode and probably perturbing the interactions with Trp412. Thus, XylE cannot make key interactions with cytochalasin B that are responsible for high-affinity binding of this inhibitor to GalP and AraE, explaining the lack of inhibition.

A comparison of the charged residues in XylE (a symporter) with their equivalents in hGLUT1 (a unipporter), and other hGLUT family members, reveals that Asp27 in XylE becomes Asn in the hGLUTs (except in hGLUT2), and the homologous residue to Glu206 in XylE is always uncharged in the hGLUTs. Thus, the residues that likely distinguish unporters from secondary transporters lie outside the substrate-binding site. The conservation of the substrate-binding site reinforces the notion that the unporters, like the secondary transporters, are capable of mediating alternate access to either side of the membrane. Substrates can bind with equal affinity from either side, commensurate with the unipporter/transporter–substrate complex, reaching the same lowest energy bound state that may lie anywhere between the outward-open and inward-open states.

In summary, we report inhibitor-bound crystal structures of WT-hGLUT1. We determined the structures with bound cytochalasin B and inhibitors GLUT-i1 and GLUT-i2. Several clashes were established for compounds to four well-characterized hGLUT family members. Docking of these compounds to hGLUT1 successfully re-created the experimentally observed binding modes. We generated homology models for hGLUT2, hGLUT3, and hGLUT4, and calculated the computed binding energies of the compounds to them. These predicted values follow the same trend as the experimentally observed activities, and thus provide insight into the basis of selectivity within the hGLUT family. This study advances the understanding of the hGLUT-binding site, which helps in the design and optimization of more specific inhibitors for the hGLUT family.

Materials and Methods

Materials. The cytochalasin B, tris(2-carboxyethyl)phosphine (TCEP), and buffers were obtained from Sigma–Aldrich. The nickel-nitritrocicacid (Ni-NTA) resin columns (1 mL) were from GE Biosciences. The n-dodecyl-β-maltopyranoside (β-DDM) and β-NG were obtained from Affymetrix. GLUT-1 and GLUT-2 were synthesized as described in SI Materials and Methods. All other materials were of reagent grade and were obtained from commercial sources.

GLUT Isoform Specificity Testing. For specificity testing between hGLUT1, hGLUT2, hGLUT3, and hGLUT4, we used DLD1 cells (for hGLUT1), DLD1Glut1 (Horizon Discovery; for hGLUT3), CHO-hGLUT2, and CHO-hGLUT4 (hGLUT2 and hGLUT4) cells in combination with an oxidative phosphorylation inhibitor (1 μM rotenone). Cell lines were maintained in DMEM/F12 with Glatumax (Thermofisher), supplemented with 10% (vol/vol) FCS (Sigma) and 1% (vol/vol) penicillin-streptomycin solution (Glubbio) under standard conditions. The cells were treated with trypsin and seeded into 384 plates at a density of 4,000 cells per well. The cells were then cultured overnight in glucose-free media containing 1% FCS to reduce intracellular ATP levels. For hGLUT1/hGLUT2/hGLUT3, after 16 h, the cells were incubated with an appropriate glucose concentration, or fructose concentration in the case of hGLUT2 (0.1 M glucose for hGLUT1, 0.3 M glucose for hGLUT3, and 30 mM fructose for hGLUT2, respectively), with or without compounds and 1 μM rotenone for 15 min. The CellTiter-Glo Luminescence Cell Viability Assay from Promega was then used to measure ATP levels.

For hGLUT4, after 16 h, the medium was removed and cells were adapted to KCl-free tyrode buffer for 3 h. Compounds and rotenone were added, and after 20 min, cells were incubated with glucose (0.1 M final concentration) for 15 min. The CellTiter-Glo Luminescence Cell Viability Assay was then used to measure ATP levels.

Protein Expression and Purification. For large-scale production of hGLUT1 for purification and crystallization trials, the full-length WT-human hGLUT1 was expressed in S. cerevisiae. A detailed description is provided in SI Materials and Methods. In brief, the protein was solubilized from yeast cell membranes in the presence of 2% (vol/vol) β-DDM at 4 °C for 2 h and purified using a deca-His affinity tag on an Ni-NTA column in the presence of 0.1% (vol/vol) β-DDM. The protein was eluted from the column in the buffer containing 25 mM MES (pH 6.0), 150 mM NaCl, 5% glycerol, 0.4% (vol/vol) β-NG, 0.5 mM TCEP, and 500 mM imidazole. The sample was dialyzed overnight in the same buffer along with thrombin but no imidazole. The sample was collected and concentrated to about 10 mg/mL.

Crystallization. Cytochalasin B, GLUT-i1, and GLUT-i2 were added to the purified protein (10 mg/mL) at a concentration of 1 mM. The ligands were mixed well and left on ice for at least 30 min before setting up the crystallization trials. The samples contained 1–2% DMSO at the time of crystallization setup. Crystals were grown at 4 °C by vapor diffusion in 200 μL wells containing 2 μL well plates with a reservoir containing 30–40% (vol/vol) PEG 400, 100 mM MES (pH 5.5–6.5), and 50–200 mM NaCl or MgCl2. Crystals were harvested from the trays and frozen directly in liquid nitrogen for data collection.

Data Processing. All datasets were collected at Lawrence Berkeley National Laboratory Advanced Light Source Beamline 8.3.1 at 100 K and at a wave-length of either 1.115 Å (cytochalasin B and GLUT-i1 complex) or the bromine absorption edge, λ = 0.903 Å (GLUT-i2 complex). The data were processed in space group C2 using MOSFLM and AIMLESS from the CCP4 suite (GLUT-i1) (23–25) or the HKL2000 packages in space group C2 (GLUT-i2 and cytochalasin B) (26). The selected resolution cutoffs were based on correlation coefficient.
The ligand in the hGLUT1-4 crystal structures and models was set as a centroid to build a grid box following Schrödinger default parameters. The Glide function (33) was used to dock an ensemble of ligand conformations in the grid-defined binding site. A maximum of 10 poses per ligand were retained and scored using the standard precision function. No constraints were applied in the docking studies.

Molecular Modeling, Prime/MM-GBSA Calculations. Prime/MM-GBSA calculations were carried out on receptor-ligand complexes obtained from the molecular docking. The free binding energy ($\Delta G_{bind}$) is calculated for each molecular species (protein, complex, and ligand) according to the following equation:

$$\Delta G_{bind} = G_{complex} - (G_{protein} + G_{ligand}).$$

The $\Delta G_{bind}$ is a sum of nonbonded electrostatic interactions (koulons), van der Waals, internal strain, and solvation energy terms. These parameters are calculated using the VSGB2.0 implicit solvent model with the OPLS-2005 force field implemented in Prime (34). The entropy term related to the ligand or protein was not included in the calculations. However, the solvent entropy term is included in the VSGB2.0 implicit solvent model.

ACKNOWLEDGMENTS. We thank John Pak for expert help with initial data analysis and J. Holton and G. Meigs for assistance with synchrotron data collection at the Advanced Light Source. We thank the University of California Office of the President, Multicampus Research Programs and Initiatives Grant MR-15-338599 and the Program for Breakthrough Biomedical Research, which is partially funded by the Jared and Andrea Sandler Foundation, for support of Beamline B3.1.3. Chimera has been developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by National Institute of General Medical Sciences Grant P41-GM103311). This work was also supported by NIH Grant R37 GM024485, the Danish Council for Independent Research (Grant DFF-4002-00052), and the European Research Council (Grant 637372).